JNS.jpgThe January issue of the Journal of the Neurological Sciences Vol 384 is now available online.


Click here to access.



Issue highlights

Resumption of antiplatelet therapy in patients with primary intracranial haemorrhage: Balancing benefits and risks

Intracranial or intracerebral haemorrhage (ICH) can be primary ICH (in the absence of a single clear underlying lesion) and secondary ICH (as a complication of a pre-existing lesion, such as vascular malformation or tumour; or antithrombotic therapy). Primary ICH is the most common type of ICH, and overall, is the second most common subtype of stroke accounting for approximately 10 to 20% of all strokes.


Neuropathic pain and SCI: Identification and treatment strategies in the 21st century

  • This review includes discussion about current classifications and tools for identification of neuropathic pain in individuals with SCI.
  • Discussion of current pharmacological and non-pharmacological treatment for NP in SCI are provided.
  • Recommendations on what tools to use for NP identification in SCI patients, and a “decision tree” for NP treatment is included.
  • This is the first review to pair identification with treatment recommendations.
Abstract Image

Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: A meta-analysis of cohort studies

Clinical disagreement over antiplatelet (AP) resumption in patients with primary intracranial hemorrhage (ICH) has long existed. This meta-analysis aimed to evaluate the benefits of AP resumption on preventing ischemic or thromboembolic events against its risks of promoting ICH recurrence or hematoma expansion.

  • Antiplatelet resumption reduced ischemic or thromboembolic risk in ICH.
  • Antiplatelet resumption did not increase the risk of ICH recurrence.
  • Antiplatelet resumption in ICH patients may be rational.
Abstract Image

Resting state fMRI studies in SPG4-linked hereditary spastic paraplegia

The study aimed to investigate the functional alterations of spontaneous brain activity in patients with spastic paraplegia type 4 (SPG4), and the relationship with the severity of spasticity.

  • The first BOLD-fMRI study for Spastic Paraplegia Type 4 (SPG4) patients
  • Baseline activity in many brain regions is altered in patients with SPG4.
  • Disturbances in SPG4-related neural networks when patients at rest is observed.


Abstract Image